Tag: Medical Research
Overcoming Challenges of Traditional Trials in Ultra-Rare Diseases: The Case of Barth Syndrome
Ultragenyx's founder and CEO, Kakkis, is at the forefront of developing another treatment for an ultra-rare disease called Barth syndrome. This genetic disorder affects around 200 boys worldwide and is caused by a mutation...
Assessing the Cost-Effectiveness of Alzheimer’s Drug Donanemab in the U.K.
The recent decision by the U.K.'s National Institute for Health and Care Excellence (NICE) regarding the cost-effectiveness of the Alzheimer's drug Donanemab, also known as Kisunla, has raised concerns about its accessibility to patients....
Bhattacharya Nears Confirmation as NIH Director
Jay Bhattacharya, the nominee for the position of Director of the National Institutes of Health, faced a confirmation hearing on Wednesday that left many questions unanswered. Despite his reluctance to make concrete statements on...
Summit Therapeutics Clinical Trial Update: What You Need to Know
Adam Feuerstein, a seasoned writer and biotech columnist, dives into the world of drug development, business, Wall Street, and biotechnology. He wears many hats as a co-host of the weekly biotech podcast The Readout...
First In Vivo Beta-Thalassemia Trial by Chinese Biotech: What to Expect
First In Vivo Beta-Thalassemia Trial by Chinese Biotech: A Groundbreaking Leap in Genetic MedicineIn a groundbreaking move that could revolutionize genetic medicine, Chinese biotech company YolTech Therapeutics has announced the initiation of the first...
Revolutionary Biotech Battle: Impact on Transplants in Mantle Cell Lymphoma
Revolutionary Biotech Battle: Impact on Transplants in Mantle Cell LymphomaIn a groundbreaking showdown at the ASH 2024 conference, the biotech world witnessed an intense rivalry between Arcellx and Legend Biotech over their anti-BCMA CAR-T...
Pfizer CEO’s Vision for Leading Cancer and Obesity Treatments
Albert Bourla, the CEO of Pfizer, is looking to shift the focus of the company from its successful COVID-19 vaccine and antiviral Paxlovid to new investments in drugs for cancer and obesity. While Pfizer's...
Kevin Hall, Top NIH Nutrition Scientist, Unlikely to Return to Agency
Kevin Hall, a top nutrition scientist who recently left the National Institutes of Health, revealed that he probably won't be making a comeback to the agency, even after NIH Director Jay Bhattacharya personally reached...
Fight for Your Science: AACR Cancer Researchers’ Urgent Call
So, like, this dude Angus Chen, right? He's all about cancer stuff - drugs, policy, science, equity, you name it. He hopped on board with STAT in 2021 after doing health and science reporting...
1984 Tribute to NIH: Valuable Insights for Today’s Physicians
In a world where the National Institutes of Health (NIH) announced drastic cuts to indirect costs, the implications for research, innovation, and healthcare are dire. These cuts threaten the very foundation of academic medicine,...
Impact of Trump Administration Health Research Cuts on Massachusetts
Amidst the bustling streets of Massachusetts, a looming shadow of uncertainty falls upon the biomedical research community. Elected leaders, including Senator Ed Markey, have sounded the alarm on the imminent impact of the Trump...
Exploring the Benefits and Risks of GLP-1s: A Comprehensive Study
GLP-1 Drugs Unveiled: Promises and Pitfalls RevealedIn a groundbreaking study published in Nature Medicine on Monday, clinical epidemiologist and nephrologist Ziyad Al-Aly from Washington University in St. Louis unveiled the comprehensive benefits and risks...
